Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Yes, the FDA has approved newer drugs for Crohn's disease, including Stelara (ustekinumab) and Hadlima (adalimumab), and selective IL-23 inhibitors are emerging as promising…
The study identified three biomarkers (ARHGEF3, S100A8, RHOU) that show high diagnostic accuracy for ulcerative colitis, but their ability to diagnose Crohn's disease…
Childhood antibiotic use is linked to a higher risk of developing inflammatory bowel disease, with a meta-analysis showing a 42% increased risk overall.
Gut microbial metabolites like short-chain fatty acids protect against colorectal cancer in IBD, while secondary bile acids, TMAO, and hydrogen sulfide promote it.
Yes, enteral nutrition therapy can help achieve remission in Chinese IBD patients, with a 60% clinical remission rate over 6 weeks, especially in Crohn's disease.
People with Crohn's disease have significantly lower oral microbial diversity compared to healthy individuals, with specific bacterial shifts and reduced butyrate metabolism.
Enteral nutrition therapy may help achieve remission in ulcerative colitis, with studies showing clinical remission rates around 60% and benefits in acute severe cases, but…
Yes, three biomarkers (ARHGEF3, S100A8, RHOU) show high diagnostic accuracy for ulcerative colitis, and bile acid ratios are also promising noninvasive markers.
Yes, inhibiting the NF-κB pathway is a key treatment strategy for ulcerative colitis, as it reduces inflammation and may prevent cancer progression.
Ulcerative colitis patients consistently show reduced gut bacterial diversity (lower Shannon index) and altered composition compared to healthy controls, with depletion of…
Yes, bowel dose-volume predictors like V30Gy and V40Gy can help estimate your risk of GI toxicity after cervical cancer radiotherapy.
Yes, a tandem-ring applicator lowers rectal and sigmoid radiation doses compared to tandem-ovoid in cervical cancer brachytherapy, based on a randomized trial.
Lab findings often don't translate to real-world HCC care due to tumor heterogeneity, racial disparities, and lack of validated biomarkers for routine use.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.